


Supplementary Table 1 Initial analysis of 50 biomarkers on a subset of 95 patients inflammatory bowel disease ($n = 54$) vs non-inflammatory bowel disease ($n = 41$), mean (SD)


Biomarker	Non-IBD ($n = 41$)	IBD ($n = 54$)	P value
IL 2	100 (43.2)	91.4 (33.9)	0.273
IL 6	96.6 (38.8)	100 (30.3)	0.601
IL 9	85.7 (39.9)	82.6 (32.1)	0.691
IL 10	69.4 (24.2)	67.5 (19.0)	0.678
IL 13	71.1 (30.9)	67.6 (20.0)	0.531
IL5	45.5 (16.0)	45.2 (13.1)	0.931
IL 4	265 (375)	201 (140)	0.311
IL 17 A	144 (108)	161 (194)	0.593
IL 17 F	236 (285)	174 (110)	0.19
IL 22	164 (109)	385 (404)	< 0.001
INF-G	108 (101)	85.3 (47.5)	0.188
TNF A	127 (146)	92.5 (53.3)	0.162
Eotaxin	130 (39.3)	150 (66.3)	0.0682
IL 8	61.5 (46.4)	39.9 (53.7)	0.0385
IP 10	85.0 (65.7)	96.1 (131)	0.59
MCP 1	564 (407)	674 (438)	0.213
RANTES	1410 (652)	1290 (877)	0.44
TARC	128 (59.6)	220 (158)	<0.001
ENA 78	636 (532)	575 (391)	0.539
CXCL1	407 (265)	672 (530)	0.00207
I TAC	187 (81.0)	207 (149)	0.394
CXCL9	341 (259)	970 (832)	<0.001
MIP 1B	192 (40.3)	200 (50.4)	0.399
MIP 1A	111 (36.6)	115 (74.3)	0.688

MIP 3A	154 (78.3)	180 (271)	0.514
CCL1	302 (236)	304 (207)	0.964
CCL7	232 (207)	222 (171)	0.815
CCL13	403 (382)	465 (432)	0.462
CCL22	894 (469)	1120 (618)	0.0484
CCL24	204 (102)	220 (198)	0.617
CCL8	1800 (1400)	2340 (2120)	0.14
CCL18	17300 (6700)	16700 (5960)	0.668
CCL19	1040 (981)	1310 (1110)	0.202
CX3CL1	420 (309)	399 (243)	0.714
CXCL2	3000 (2800)	4100 (4450)	0.142
CXCL12	7230 (5120)	7320 (4640)	0.927
CXCL13	1890 (2550)	1950 (1880)	0.893
GM-CSF	165 (41.4)	168 (47.8)	0.718
IFN-A2	131 (41.8)	121 (26.7)	0.206
IL-1A	96.9 (46.7)	96.3 (54.8)	0.954
IL-1B	164 (56.4)	158 (27.8)	0.567
IL-23	127 (54.4)	115 (25.5)	0.188
TSLP	581 (609)	405 (678)	0.186
IL-11	207 (55.6)	198 (34.8)	0.347
IL-12p40	187 (132)	170 (79.8)	0.458
IL-12p70	131 (84.8)	111 (31.8)	0.159
IL-15	206 (104)	188 (67.5)	0.351
IL-18	1190 (566)	1740 (1010)	0.00149
IL-27	295 (70.5)	291 (75.1)	0.794

A table of univariate analysis discriminating between inflammatory bowel disease (IBD) and non-IBD patients.



Supplementary Figure 1 Biomarker importance.



Supplementary Figure 2 χ^2 analysis.